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1. Introduction 
1.1 Structural myocardial diseases – a challenge in 
classification, diagnosis and therapy  
Structural myocardial diseases represent a large and heterogenous group of 
cardiac diseases with various clinical phenotypes including arrhythmic events, 
heart failure and even sudden cardiac death.  
The underlying cardiomyopathies (CM) are a complex group of heart muscle 
diseases with multiple etiologies making the classification of CM especially 
difficult.  
According to the classification by the American Heart Association (AHA 2006) 
CM are divided in two main categories: primary and secondary CM. Primary CM 
can be genetic, mixed or acquired, whereas secondary CM constitute to be a 
part of a systemic disorder [1]. In primary CM the heart is the predominantly 
involved organ whereas in secondary CM the myocardial dysfunction is caused 
by the underlying disease.  
There is a different classification suggested by the European Society of 
Cardiology (ESC 2008) according to which CM “are grouped into specific 
morphological and functional phenotypes; each phenotype is then sub-classified 
into familial and non-familial forms”. Exact definitions of CM are given below. 
Progression of cardiomyopathies can be irreversible leading to congestive heart 
failure. The affection of the myocardium, especially the degree of cardiac 
inflammation, fibrosis and subsequent dysfunction of the myocardium and 
impairment of the left ventricular function is a limiting factor of the patients’ 
prognosis in primary and secondary CM.  
Since heart failure is the third most common cause of death in Germany after 
chronic ischemic heart disease and acute myocardial infarction (Statistisches 
Bundesamt 2010), it is of great importance to diagnose and treat CM at an early 
stage of the disease. In the United States it is estimated that 5-10% of patients 
with congestive heart failure are diagnosed with some type of CM [2].  
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The diagnosis of CM involves established examination methods like 
echocardiography, cardiac magnetic resonance imaging, heart catheterization, 
endomyocardial biopsy, and electrophysiological risk stratification. The etiology 
remains unknown in 50% of patients [3].  
Patients with CM need either a long term pharmacological treatment or 
implantable device therapy (cardiac resynchronization therapy (CRT), 
cardioverter-defibrillators (ICDs) and/or ventricular assist device), and in cases 
of end stage disease heart transplantation. Despite these therapeutic options 
the prognosis remains poor so far [3, 4].  
The individual risk assessment is crucial for the clinical decision process. There 
are clinical factors associated with an adverse clinical outcome like New York 
Heart Association (NYHA) class ≥ III [5-8], low ventricular ejection fraction 
(LVEF) [9-12] or elevated B-type natriuretic peptide (BNP) [13].   
However, there are no established histological criteria or markers to classify the 
severity of CM or to assess the short-term and long-term prognosis. Such 
markers would give us the opportunity to predict the outcome of the disease 
and thus providing individual and causal treatment approaches at an early stage 
of the disease.  
 
1.1.1 Definition of cardiomyopathies according to ESC 
classification 
According to ESC classification CM is a myocardial disorder in which the heart 
muscle is structurally and functionally abnormal, in the absence of coronary 
artery disease, hypertension, valvular disease and congenital heart disease 
[14]. They are classified according to functional and morphological criteria as 
dilated, hypertrophic, arrhythmogenic right ventricular, restrictive and 
unclassified CM. According to etiology CM can be genetic or nongenetic, with 
nongenetic being divided into acquired or idiopathic. 
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1.1.1.1 Dilated cardiomyopathy (DCM) 
DCM is the most common CM worldwide defined by the presence of left 
ventricular dilation and left ventricular systolic dysfunction [15]. The right 
ventricle can be dilated and the right ventricular function is often impaired. DCM 
can be genetic, idiopathic or acquired. The prevalence of idiopathic DCM is 
estimated as 1:2500 and is a CM of unknown cause. It appears in men twice as 
often in comparison to women and most often in middle age. The acquired DCM 
can be caused by myocarditis and toxical factors (toxins, alcohol, drug abuse 
and anthracycline). Systemic infections (viral, bacterial, fungal, parasitic) and 
especially viral infections (B19 parvovirus, adenovirus, coxsackievirus B) can 
lead to myocardial infection after an interval of some days. This leads to a 
myocardial inflammation and myocardial dysfunction. Acquired DCM is also 
caused by systemic underlying diseases. Patients with autoimmune systemic 
(lupus erythematosus, polymyositis, sklerodermie, rheumatoid arthritis, Churg 
Strauss syndrome, sarkoidosis, amyloidosis), neuromuscular (myotonic 
dystrophy, Morbus Friedrich), metabolic (Morbus Gaucher, haemochromatosis) 
or endocrine disorders (hyper/hypo-thyreosis, diabetes mellitus) are often 
diagnosed with DCM. Genetic DCM is found in 35% of patients. The disease is 
predominantly inherited in an autosomal dominant pattern. Sarcomeric protein, 
Z-band, cytoskeletal genes and nuclear membrane mutations are reported in 
the disease [1]. In the myocardium of patients with DCM the structure of fibers 
becomes anomalous and areas with interstitial and perivascular fibrosis are 
detected. Parts of the myocardium can be necrotic, showing cellular infiltration 
[15]. This process leads to cardiac remodeling of one or both ventricles. 
Patients with DCM gradually develop heart failure, ventricular and 
supraventricular arrhythmias and depending on the risk for sudden cardiac 
death (SCD) they often need an ICD implantation [1].  
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1.1.1.2 Hypertrophic cardiomyopathy (HCM) 
HCM is a genetic CM based on sarcomere disorder. It is characterized by a 
hypertrophied but in the start non-dilated left ventricle (LV). The LV wall 
thickness is increased (>13mm). That makes the LV stiff and leads to diastolic 
filling disorder and elevated end-diastolic pressure. Gradually, the LV dilates 
and patients develop systolic dysfunction. The majority of the patients have an 
asymmetrical pattern of hypertrophy, which is mainly detected in the anterior 
septum [16]. HCM is classified in hypertrophic obstructive CM (HOCM) and 
hypertrophic non-obstructive CM (HNCM) depending on the presence of LV 
outflow tract obstruction. Late gadolinium enhancement (LGE) detected by 
cardiac magnetic resonance (CMR) is present in 60% of patients with HCM and 
LV hypertrophy which is why CMR is used for risk stratification in HCM [17]. The 
disease is caused by a gene mutation of sarcomeric proteins which is inherited 
in an autosomal dominant pattern. The prevalence in the general population is 
about 1:500. Histological analysis reveals hypertrophied cardiomyocytes which 
are distributed in the LV in a disorganized way and alter the normal LV 
architecture. The increased formation of intimal and medial collagen in the wall 
of coronary vessels leads to a small vessel disease and myocardial ischemia. 
The abnormal structure of the myocardium tissue after the cardiomyocyte death 
and the formation of myocardial scarring finally contributes to life-threatening 
arrhythmias like ventricular tachycardia (VT), ventricular fibrillation (VF) and 
consequently to SCD [1]. The annual incidence of SCD is approximately 1%. 
Prior cardiac arrest (due to VF, VT), spontaneous sustained VT and syncope of 
undetermined origin with clinically relevant, haemodynamically significant 
sustained VT or VF induced at electrophysiological study are major risk factors 
for SCD and according to American College of Cardiology (ACC) / AHA 
guidelines they are a class I indication for ICD implantation [18]. Moreover, 
other risk factors like family history of SCD, unexplained syncope, non-
sustained VT (nsVT), abnormal blood pressure during exercise and extreme left 
ventricular hypertrophy (maximum dimension ≥ 3cm) highly increase the risk for 
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SCD, which is why patients with one or more of these factors  have  a class IIa 
indication for ICD implantation [19].  
 
1.1.1.3 Arrhythmogenic right ventricular 
cardiomyopathy (ARVC)  
ARVC is an uncommon CM characterized by the presence of right ventricular 
systolic/diastolic dysfunction and global or regional abnormal structure of the 
right ventricle (RV) (RV dilatation and RV aneurysms). In patients with ARVC 
the cardiomyocytes are progressively replaced by fatty and fibrous tissue. In 
two thirds of the patients there is also a fibrous replacement of the myocardium 
of the LV and LV enlargement. Other important morphological patterns of ARVC 
are focal thinning of ventricular free wall, wall hypertrophy, focal bulging of the 
RV wall in diastole and right ventricular outflow tract (RVOT) enlargement. CMR 
is a valuable tool for evaluation of cardiac structure and function in ARVC [20]. A 
definitive diagnosis however is based on histological demonstration of 
transmural fibrous and/or fibrofatty replacement of RV myocardium at biopsy. 
The prevalence is estimated between 1:2000 and 1:5000 and it is more 
commonly seen in males. It is associated  with SCD in young people and 
athletes [21]. ARVC is predominantly autosomal dominant inherited. Mutations 
in genes encoding for desmoplakin, plakophilin-2, plakoglobin, desmoglein-2, 
ryanodine receptor RyR2 and transforming growth factor beta (TGF-ß) are 
recognized in the disease. The abnormal structure of the RV can lead to fatal 
VTs. The induction of fast unstable VT/VF at electrophysiological study has 
been  shown as independent predictor of life-threatening events [22]. These 
data may be valuable for identifying individuals at risk in an early stage. Anti-
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1.1.1.4 Restrictive cardiomyopathy (RCM) 
RCM is a rare CM characterized by diastolic dysfunction due to increased 
stiffness of the left ventricular wall. End diastolic pressure is increased in both 
ventricles with only a small elevation of the volume. The LV wall thickness and 
the atrioventricular valves remain normal whereas the atria are significantly 
dilated. The ventricular filling is defective but the systolic function is preserved. 
A wide spectrum of systematic disease like amyloidosis, sarcoidosis, 
haemochromatosis, carcinoid heart disease, scleroderma and anthracycline 
toxicity can lead to acquired RCM. Loeffler endocarditis is a specific form of 
restrictive CM and usually a late manifestation of hypereosinophilic syndrome. 
Patients with end-stage HCM, DCM and endocardial fibrosis and fibroelastosis 
are also very often diagnosed with RCM.  The familial type of the disease is 
autosomal dominant inherited with gene mutation of troponin I and desmin. 
RCM is believed to have the lowest prevalence in the population of all types of 
CM [14]. 
 
1.1.1.5 Unclassified cardiomyopathies 
This category encompasses CMs which do not have the typical characteristics 
of one of the other 4 groups. Left ventricular non compaction CM (NCCM) is a 
rare congenital CM (1:2000 echocardiographic studies) which is believed to be 
caused by arrest of normal embryogenesis of the endocardium and 
myocardium. LV appears to be spongy and “non-compacted” and consists of a 
meshwork of numerous muscle bands called trabeculations with deep 
intertrabecular recesses. NCCM can be familial (40%) and may occur 
sporadically. Clinical manifestations vary from no symptoms to congestive heart 
failure, arrhythmias, and embolic events [23]. Takotsubo CM is a non-ischaemic 
CM which is triggered by endogenous or iatrogenic catecholamine excess . It is 
also called stress-induced CM or transient apical ballooning syndrome. It is 
characterized by transient and severe left ventricular apical ballooning and 
basal hyperkinesia. Clinical manifestation is the sudden onset of congestive 
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heart failure. In the acute phase of this CM the patients have symptoms similar 
to an acute coronary syndrome (dyspnea, chest pain) and the ECG changes 
are suggestive of an anterior wall myocardial infarction. About 70 - 80% of the 
cases occur in post-menopausal women. LV function usually recovers   within 2 
months [24]. 
 
1.2 Prognostic impact of myocardial inflammation and 
fibrosis in structural myocardial diseases  
The prognosis of structural myocardial disease has been linked to the degree of 
inflammation and the amount of fibrosis within the myocardium. Inflammatory 
mechanisms in structural myocardial diseases comprise the recruitment of 
inflammatory cells to myocardial sites of injury and dysfunction. Specific 
humoral and cellular factors like proinflammatory cytokines, matrix metallo-
proteinases (MMPs) and reactive oxygen species play a distinct role in the 
process of cardiac remodeling and lead to myocardial fibrosis [25]. 
 
1.2.1 Proinflammatory cytokines 
Interleukin 1 (IL)-1β, interleukin 6 (IL)-6 and tumor necrosis factor (TNF)-α are 
cytokines that play an important role in the inflammatory processes that are 
involved in cardiac remodeling due to an underlying structural myocardial 
disease. In congestive heart failure cytokines are produced from the 
myocardium because of haemodynamic overload. It is also believed that there 
is an extramyocardial peripheral production due to hypoxia and tissue 
hypoperfusion [25]. The increased expression of cytokines leads to monocyte 
phenotype transition and necrosis of cardiomyocytes. They further activate 
MMPs, a proteolytic enzyme family which degrades the cardiac extracellular 
matrix (ECM) and leads to the modification of the interstitial matrix. 
Consequently proinflammatory cytokines lead to adverse LV remodeling and 
fibrosis process [26]. 
  13 
1.2.2 Matrix metalloproteinases (MMPs) 
MMPs are zinc-dependent proteases which belong to the metzincin superfamily. 
They degrade ECM and play an important role in normal tissue remodeling. At 
the same time uncontrolled increase in MMP activity leads to excessive ECM 
degradation and pathological tissue remodeling. By the digestion of ECM 
matrikines are released [27]. They are peptides that contribute to chemotaxis in 
many cell types and induce the production of cytokines and growth factors. 
Consequently they play a role in new connective tissue formation. Furthermore, 
MMPs release platelet derived growth factor (PDGF), active transforming 
growth factor beta1 (TGFß1) and insulin-like growth factor (IGF) through the 
digestion of the ECM. They are active factors associated with ECM that control 
the cell activity (proliferation, differentiation) and play a role in formation and 
remodeling of ECM [28]. With this mechanism MMPs lead to the progression of 
fibrotic processes of the myocardium. 
 
1.2.3 Oxidative stress 
Chronically elevated oxidative stress in myocardium also plays a role in the 
mechanism of cardiac remodeling. Reactive Oxygen Species (ROS) are highly 
reactive molecules, produced by the normal metabolism of oxygen. ROS 
production is a normal component of oxidative phosphorylation; however, 
disregulation of ROS generation can play a role in cell dysfunction. Higher but 
not cytotoxic levels of ROS and signaling through 1-andrenergic-receptor or 
angiotensin-receptors apparently induce mitochondria dependent apoptosis in 
myocytes. High mechanical strain causing strong ROS-production and 1-
andrenergic-receptor induce apoptosis, probably through ROS dependent 
activation of c-Jun N-terminal kinases. Under low mechanical strain lower levels 
of ROS are produced. Together with stimulation through angiotensin-, TNF-a, 
endothelin or a1-andrenergic receptors kinase cascades are activated 
culminating in an activation of gene expression for cell growth leading to 
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myocyte hypertrophy.   Moreover, oxidative stress stimulates cardiac fibroblast 
proliferation and activates MMPs and leads to cardiac tissue remodeling [29]. 
 
1.3 Impact of molecular and immunohistochemical 
biomarkers in structural myocardial diseases for risk 
stratification  
1.3.1 Impact of Cyclophilin A and Extracellular Matrix 
Metalloproteinase Inducer (EMMPRIN) as risk 
markers in structural myocardial diseases 
Cyclophilin A (CypA) is a cyclosporine binding-protein. CypA expression in 
patients with coxsackievirus B3-induced myocarditis is found to promote the 
recruitment of macrophages and T-cells and so it is believed to play a 
significant role in the pathogenesis of inflammatory CM [30]. Recently it was 
shown that CypA is an independent predictor of clinical outcome in patients with 
congestive heart failure [31].  
EMMPRIN is a transmembrane glycoprotein which is expressed by leukocytes, 
epithelial and endothelial cells. It is a type I integral membrane receptor binding 
with many ligands such as CypA and Cyclophilin B (CypB) amongst others. 
EMMPRIN is significantly highly expressed in patients with inflammatory CM 
and can serve as a marker of myocardial remodeling. However, in non- 
inflammatory CM it is only slightly upregulated [32]. 
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1.3.2 Inflammatory markers in standard histopathology 
and immunohistochemistry: Major Histo-
compatibility Complex Class II, CD 3 and CD 68 
Major Histocompatibility Complex (MHC) Class II molecules are extracellular 
proteins which are found on antigen-presenting cells and lymphocytes. In CD4+ 
T-cells recognition of antigens presented on MHC-II activate T-cells which can 
regulate the immune response and inflammation. By this mechanism MHCII 
expression is believed to play a role in inflammatory heart disease [33]. MHCII 
expression is found to be strongly connected with the expression of other 
myocardial inflammation markers like CypA, CD68, CD3 in myocytes of patients 
with CVB3-induced myocarditis [30].  
CD3 is a transmembrane receptor on the surface of T-cells. In 
immunohistochemistry it is used as marker of T-cells in tissue specimens. CD3 
expression was shown to have a strong correlation with the expression of CypA 
and EMMPRIN in myocardial tissue sections of patients with inflammatory CM 
and is regarded as marker of myocardial inflammation [30]. 
CD68 is an intracellular glycoprotein that is also expressed on the surface of 
monocytes and macrophages. It is used as marker for macrophages in 
immunohistochemical stainings. Macrophage infiltration, detected by CD68 
staining, plays an important role in inflammatory processes of myocardium. Its 
expression in tissue sections of endomyocardial biopsies of patients with CVB3-
induced myocarditis is significantly correlated with the expression of CypA, 
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1.4 Impact of Gremlin-1 in the adult organism and in 
fibrosis 
Gremlin-1 (Grem1) is a member of the DAN and cerberus protein family, a 
subgroup of the cysteine knot superfamily which are antagonists of bone 
morphogenetic proteins (BMPs). Grem1 is a 184 amino-acid protein with a size 
of 20.7 kDa. It exists in two isoforms, a secreted and a cell-associated one [34].  
At first Grem1 was identified as a novel gene named drm that was 
transcriptionally down-regulated in v-mos-transformed fibroblasts of rat embryos 
[35]. In 1998 at the Department of Molecular and Cell Biology in the University 
of California, Berkeley, this gene was renamed Gremlin and was shown to be 
expressed in the neural crest of Xenopus embryos and plays a role in 
embryonic development [36]. Nowadays, the role of Grem1 in embryogenesis is 
well described. Grem1 expression contributes to lung, kidney and limbs 
development [37]. Its expression is also crucial for cardiogenesis, angiogenesis, 
setup of the anterior-posterior body axis and left-right symmetry [38, 39] Grem1 
inhibits monocyte chemotaxis by interacting with Slit1 and Slit2 proteins [40] . 
Furthermore, it interacts directly with endothelial cells and plays a significant 
role as proangiogenic factor in angiogenesis, suggesting Grem1 as a possible 
target in cancer treatment [41] .  
Interestingly, in adults Grem1 expression is also shown to be involved in chronic 
inflammatory diseases leading to fibrotic remodeling of organs, like lungs, 
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1.4.1 Interaction of Gremlin-1, bone morphogenetic 
proteins and transforming growth factor beta: 
Characterization of the signaling pathways 
Transforming growth factor beta (TGF-ß) is a cytokine that plays an important 
role in regulating many cell functions like cell proliferation and differentiation. It 
is a secreted protein, found in 3 isoforms TGF-ß1, TGF-ß2 and TGF-ß3. TGF-ß 
acts on epithelial cells and is a protein secreted by many cell types. Through 
TGF-ß/Smad (Small tail and mothers against decapentaplegic)-signaling 
pathway TGF-ß leads to epithelial to mesenchymal transition (EMT), a process 
which is shown to contribute to fibrinogenesis [42]. Smads are intracellular 
proteins that transfer the signals from TGF-ß ligands binding on cell surface to 
the nucleus. Binding of the receptor with the TGF-ß ligand leads to the 
activation of Smad3, which is a receptor-associated Smad (R-Smad). The 
phosphorylated R-Smad binds to a Smad4, which is a common Smad 
(coSmad). This complex is then transferred into the nucleus and leads to the 
transcription of various genes. In epithelial cells of patients with kidney fibrosis 
the TGF-ß/Smad signaling pathway is found to promote EMT [43]. 
BMPs are a family of 20 cytokines, members of the TGF-ß superfamily. They 
have a morphogenetic role in embryonic development and the normal formation 
of many tissues. BMPs promote osteoblast differentiation and induce bone 
formation. They also induce kidney and heart development and regulate hepatic 
glucose homoeostasis and fertility [45]. BMPs induce cell regeneration and 
mediate apoptosis of myofibroblasts. BMP-7 is shown to play a role in reducing 
the release of proinflammatory cytokines at epithelial cells of kidney tissue and 
it counteracts the TGF-ß/Smad signaling in those cells [42]. 
Grem1 inhibits BMP-2,-4 and -7. The mechanisms of inhibition can be either 
extra- or intra-cellular. Through extracellular binding with secreted BMPs, 
Grem1 prevents the BMP ligand to bind with its receptor on cell surface. 
Through intracellular antagonism, Grem1 binds the BMP precursor protein and 
prevents the secretion of the mature protein. Moreover, Grem1 has the ability to 
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Figure 1. Grem1 antagonism in vascular cells: (A) extracellular BMP inhibition through binding 
of secreted BMP by Grem1 (B) intracellular BMP inhibition through Grem1 binding with BMP 
precursor protein (C) direct binding of Grem1 with surface of vascular cells through Grem1 
binding to slit proteins. According to Costello et al. [37] 
 
The overexpression of Grem1 leads to reduction of BMP signaling and to up-
regulation of the profibrotic TGF-ß signaling. TGF-ß itself induces the Grem1 
production (positive feedback). Promoting the TGF-ß-induced EMT Grem1 
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1.4.2 Gremlin-1 and fibrosis  
1.4.2.1 Gremlin-1 and kidney fibrosis 
      Grem1 expression plays a significant role in renal embryogenesis but its 
expression is supposed to be silent in the normal adult kidney. In patients with 
chronic kidney disease (CKD) it is shown that Grem1 is reactivated and induces 
the EMT. EMT is a mechanism by which the adult kidney epithelium responds to 
injury. During this process, the cells of the injured epithelium, which are 
characterized by phenotypic plasticity, lose the epithelial characteristics and 
convert to mesenchymal cells losing polarity, cell-cell adhesion and gaining 
motility, Figure 2. 
Figure 2. The process of EMT. The epithelial cells lose their polarity, their epithelial markers 
(listed on left side), gain mesenchymal markers (listed on right side) and mobility, and finally 
turn into mesenchymal cells. According to Kalluri et al. [46] 
 
      The epithelial cells avoid apoptosis and migrate into tubulointerstitium because 
of their fibroblasts phenotype. Through this mechanism fibrogenesis in 
tubulointerstitium is promoted. This is how Grem1 expression is believed to lead 
to ECM accumulation in interstitial place and atrophied tubular structure, 
contributing eventually to renal fibrosis [42]. With the same mechanism Grem1 
expression in parietal epithelial glomerular cells of patients with pauci-immune 
crescentic glomerulonephritis is believed to play a role in the pathogenetic 
profile of the disease. TGF-ß induces the Grem1 expression. The parietal 
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epithelial cells undergo EMT and convert to fibroblasts which contribute to the 
scar formation of crescentic glomerulonephritis [43].   
 
1.4.2.2 Gremlin-1 and idiopathic pulmonary fibrosis 
By inhibiting BMP-4-mediated signals, Grem1 is believed to play a significant 
role in lung development. Both, loss and overexpression of the gene leads to 
abnormal lung formation. Increased expression of Grem1 is detected in the lung 
interstitium of patients with idiopathic pulmonary fibrosis (IPF). IPF is a disease 
characterized by fibroproliferation, tissue destruction and excessive 
accumulation of ECM. The cells of injured lung epithelium undergo EMT as 
response to TGF-ß signaling [47]. BMPs normally induce regeneration of the 
epithelium and myofibroblasts apoptosis. Grem1 as BMP inhibitor inhibits this 
process and leads to ECM accumulation. With this mechanism Grem1 is shown 
to play a significant role in IPF. Furthermore, Grem1 overexpression in 
pulmonary microvascular endothelial cells and smooth muscle cells induces the 
apoptosis of the endothelium and the uncontrolled proliferation of the smooth 
muscle cells. This promotes the vessel inflammation and is believed to 
contribute to pulmonary hypertension [37], Figure 3. 
 
 
Figure 3. Contribution of excessive Grem1 expression to cellular changes in the lung. Grem1 
inhibits BMP induced epithelial regeneration and BMP mediated apoptosis of myofibroblasts 
and leads to ECM accumulation. High levels of Grem1 lead to uncontrolled proliferation of 
smooth muscle cells and promote damage to the endothelium, causing inflammation. According 
to Costello et al [37]. 
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1.4.2.3 Gremlin-1 and liver fibrosis 
Liver fibrosis is a progressive disease which is caused by various reasons like 
viral hepatitis, parasitic infection, metabolic and autoimmune disorders, 
congenital abnormalities and drugs and alcohol abuse. All these disorders lead 
to chronic liver injury and contribute to hepatic impairment, fibrosis and finally 
cirrhosis. In the activated hepatic stellate cells (HSC) of fibrotic livers of mice 
increased expression of Grem1 is reported. Cytokines, TGF-ß and oxidative 
stress induce the quiescent hepatic stellate cells activation. Through activation 
the cells lose a part of their retinoid storage capacity and they transform into 
myofibroblasts. The cell proliferation becomes excessive and ECM is 
increasingly produced. At the same time, during the HSC transdifferentiation the 
expression of MMP-inhibitors like tissue inhibitor of metalloproteinases (TIMP) 
TIMP-1 and -2 and the plasminogen activator inhibitor type 1 are induced. 
Consequently, the degradation of ECM is reduced. The combination of 
increased ECM production and decreased degradation due to Grem1 
expression on hepatic cells is believed to lead to ECM accumulation and 
fibrosis. Finally, Grem1 could be used as specific marker of hepatic fibrogenesis 
and inhibition of its expression could be beneficial for patients suffering from the 
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1.5 Hypothesis 
The lack of established histological criteria or markers to classify the severity of 
the structural myocardial diseases leads to the urgent need to find new 
biomarkers which could assess the short-term and long-term prognosis. A 
biomarker with high prognostic impact could be used in routine histological 
staining and contribute to the identification of patients with CM who have a high 
risk for sudden cardiac death and heart failure at early stages of the disease. 
Grem1 is a biomarker whose expression correlates with the formation of fibrotic 
tissue in kidney, lung and liver. Until now not much is known about its role in the 
process of fibrosis in human myocardium. 
Since Grem1 is a BMP antagonist that plays a role in chronic fibrotic diseases 
of other organs and since myocardial fibrosis is a key step in the 
pathophysiology of myocardial remodeling, we hypothesized that the expression 
of Grem1 may play a role in structural myocardial disease and might have a 
predictive value in the diagnostic workup of patients with structural myocardial 
disease. 
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2. Materials and methods 
2.1 Materials 
2.1.1 Antibodies 
Primary Antibodies     
Antigen Host Species Reactivity Manufacturer 
CD3 Mouse, monoclonal human 
Novocastra Laboratories, 
Newcastle on Tyne, UK 
CD68 Mouse, monoclonal human Dako, Hamburg, Germany 
HLA-DR-  Mouse, monoclonal human Dako, Hamburg, Germany 
Gremlin 1 Rabbit, polyclonal human 
Biozol/Abnova,  Eching, 
Germany 
Gremlin 1 Rabbit, polyclonal mouse Abcam, Cambridge, UK 
Actin Rabbit, polyclonal mouse Abcam, Cambridge, UK 
    
Secondary antibodies    
Anti-mouse Rabbit, polyclonal mouse Dako, Hamburg, Germany 
Anti-rabbit Goat, polyclonal rabbit Dako, Hamburg, Germany 
Anti-rabbit Donkey rabbit 




Isotype Species Manufacturer 
IgG1 Mouse Dako, Hamburg, Germany 
IgG, polyconal Rabbit Dako, Hamburg, Germany 
 
2.1.2 Kits 
iQ SYBR Green Supermix    Bio-Rad, Munich, Germany 
Biorad Protein Assay    Bio-Rad, Munich, Germany 
RNEasy Mini kit for RNA Isolation   Qiagen, Hilden, Germany 
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Vectastain Elite ABC Kit     Vector, Burlingame, USA 
 
2.1.3 Software 
ImageJ Software  National Institutes of Health, 
USA 
SPSS Software version 19.0                      IBM, USA 
 
2.1.4 Chemicals and reagents 
 
Acid fuchsin  Sigma, St. Louis, USA 
Citric acid  Sigma, St. Louis, USA 
Eosin powder  Roth, Karlsruhe, Germany 
Giemsa-solution  Sigma, St. Louis, USA 
Glacial acetic acid  Merck, Darmstadt, Germany 
Hemalum stock solution    Merck, Darmstadt, Germany 
Hydrogen peroxide     Merck, Darmstadt, Germany 
Immobilon-FL PVDF Membrane  Merck Millipore, Schwalbach, 
Germany 
Light Green SF Yellowish  Sigma, St. Louis, USA 
Orange G  Sigma, St. Louis, USA 
Ponceau S       Roth, Karlsruhe, Germany 
Protein block serum free    Dako, Hamburg, Germany 
RNAlater  Life Technologies GmbH, 
Darmstadt Germany 
Roti Histol                                            Roth, Karlsruhe, Germany 
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Roti Histokitt  Roth, Karlsruhe, Germany 
Sodium phosphotungstate hydrate   Sigma, St. Louis, USA 
Trisodium citrate dihydrate   Merck, Darmstadt Germany 
Weigert’s iron hematoxylin Solution A Roth, Karlsruhe, Germany 
Weigert’s iron hematoxylin Solution B Roth, Karlsruhe, Germany 
 
Aqueous acetic acid:  
200ml distilled water 
15 drops of glacial acetic acid 
 
Citrate buffer, pH6: 
41ml 0.1M Trisodium citrate dehydrate (2.94g dissolved in 100ml aq. dest) 
9ml 0.1M Citric acid (1.92g dissolved in 100ml aq. dest) 
450ml Aqua dest. 
pH adjusted to 6.0 before use 
 
1% Eosin staining solution: 
200ml distilled water 
2g Eosin powder 
1 drop glacial acetic acid 
 
Giemsa staining solution: 
80ml distilled water 
20ml Giemsa-solution (Sigma) 
3-5 drops of glacial acetic acid 
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Hemalum staining solution:  
160ml distilled water 
40ml Hemalum stock solution 
Filtrated through folded filter paper 
 
Light Green SF Yellowish stain solution: 
0.6g Light Green SF Yellowish 
0.6ml glacial acetic acid  
300ml distilled water 
 
 
Phosphotungstic acid – Orange G stain solution: 
12g Sodium phosphotungstate hydrate  
6g Orange G  
300ml distilled water 
 
Ponceau-acid fuchsin stain solution: 
0.2 g Ponceau S  
0.1g Acid fuchsin 
0.6ml glacial acetic acid 
300ml distilled water 
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Weigert’s iron hematoxylin stain solution: 
100ml of Weigert’s iron hematoxylin Solution A 
100ml of Weigert’s iron hematoxylin Solution B 
 
2.1.5 Clinical and lab equipment 
 
Biopsy forceps  Cordis Corporation, Waterloo, 
Belgium 
iE33 Transthoracic echocardiography  Philips Medical Systems, 
Hamburg, Germany 
Odyssey infrared imaging system LI-COR Biosciences, Bad 
Homburg, Germany 
PerfectBlue Semi-dry Electro Blotter Peqlab Biotechnologie GmbH, 
Erlangen, Germany 
XCell Sure Lock Mini-Cell  Life Technologies GmbH, 
Darmstadt, Germany 
 
2.2 Study design and assessment of risk factors 
The study enrolled 214 consecutive patients who underwent endomyocardial 
biopsy as part of the routine clinical evaluation for suspected structural 
myocardial disease at our university hospital from August 2007 until November 
2010 . 
Patients were included if they showed either impaired global or regional left 
ventricular function, enlargement of the LV, myocardial hypertrophy, or 
abnormal myocardial texture in echocardiography suggesting a structural 
myocardial disease. Significant coronary artery disease (> 50% diameter 
luminal stenosis of two or more epicardial vessels or left main or proximal left 
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anterior descending coronary artery stenosis > 50%) was ruled out by coronary 
angiography in all patients [48]. 
A careful history and physical examination as well as laboratory testings were 
collected of all patients at enrollment. Risk factors included LVEF, left 
ventricular enddiastolic diameter (LVEED), NYHA functional class, troponin I 
(TnI) and BNP.  
LVEF was measured by contrast ventriculography in the 30° right anterior 
oblique and in the 60° left anterior oblique views in all  patients undergoing 
cardiac catheterization. LVEDD was analyzed by 2-dimensionally guided M-
mode echocardiography in all patients [48]. 
All patients received medication according to current ESC and ACC/AHA 
guidelines depending on their left ventricular function and heart failure 
symptoms [49] . 
The study conformed to the principles outlined in the Declaration of Helsinki, 
and informed consent was obtained from all patients. The study was approved 
by the local ethics committee (Project-No. 253/2009BO2). 
 
2.3 Study end points and follow-up  
Patients were scheduled in our outpatient clinic for clinical follow-up every 6 
months. Patients who missed their follow-up visit were contacted by telephone 
for an interview. None of the patients was lost during follow-up .  
 
Study endpoint was a combination of all-cause of death or re-hospitalization 
due to heart failure within a follow-up period of 3 years. The occurence of an 
end point and all clinical events were reviewed by an independent end point 
committee [48].  
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2.4 Endomyocardial biopsy  
Biopsy sample site was the right or left ventricle (84.1% right ventricular 
septum) and at least six specimens with a diameter of 1 to 3 mm were 
harvested. Biopsy samples were taken with a dedicated bioptome advanced 
through various 7F coronary guiding catheters. Samples were immediately fixed 
under sterile conditions in 4% buffered formaldehyde for haematoxylin and 
eosin (HE), Masson’s trichrome, and Giemsa staining or further 
immunohistochemistry. 4µm thick paraffin-embedded tissue sections were 
stained and examined by light microscopy. Other samples were quick-frozen or 
fixed in RNA-later for PCR detection of viral genomes [50-54] [48].  
 
2.5. Histology and immunohistochemistry 
2.5.1 Histology 
For histological analysis fixed biopsy samples were deparaffinized and 
afterwards stained according to protocols for hematoxylin and eosin (HE), 
Masson’s trichrome or Giemsa staining.  
Hematoxylin-Eosin staining is used as a diagnostic tool in medical practice to 
differentially stain tissue. Nuclei are colored blue by haematoxylin while 
eosinophilic structures such as cytoplasm, Lewy bodies, Mallory bodies, red 
blood cells and collagen are colored pink to red by eosin. 
Masson’s trichrome is a routine three color stain used in histopathology to 
detect collagen fibers in different tissues. Nuclei are stained black, collagen 
fibers blue, the background red so the cells can be distinguished from the 
connective tissue.  
Giemsa staining is widely used in cytogenetics as it stains chromosomes by 
interacting with DNA and as differential stain for the histopathological diagnosis 
of several parasitic infections. It is also a classic stain for peripheral blood 
smears. Erythrocytes, lymphocyte cytoplasm, platelets, monocytes and 
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leukocytes are stained differently so that they can be distinguished during 
microscopy. Giemsa staining colors nuclei dark blue, the cytoplasm light blue 
and the collagen pale pink. 
Deparaffinization and rehydration was achieved by incubation in Roti-Histol 
twice for 10 minutes each and ethanol in descending concentrations, 100% 
ethanol twice for 5 minutes, 96% and 70% ethanol for 5 minutes each. 
For hematoxylin and eosin staining slides were washed after deparaffinization 
for 5 minutes in distilled water and incubated in Mayer’s hemalum for 5 minutes. 
Slides were washed in distilled water and incubated in warm running tap water 
for 15 minutes. After staining for 3 minutes in 1% Eosin, slides were washed in 
distilled water and dehydrated in an ascending alcohol dilution series 70% - 
80% - 96% ethanol (10 seconds each), 100% ethanol (twice 5 minutes each) 
and Roti Histol (5min) and mounted with a Roti-Histokitt. 
For Masson’s trichrome staining slides were incubated for 5 minutes in distilled 
water after deparaffinization and then incubated for 2 minutes in Weigert’s iron 
hematoxylin. The slides were then washed in tap water and incubated in warm 
running tap water for 15 minutes. Following an incubation in ponceau-acid 
fuchsin for 5 minutes, slides were washed in distilled water and incubated in 
phosphotungstic acid – Orange G for 10 minutes. Slides were washed again in 
distilled water and incubated in light green SF yellowish for 5 minutes. After a 
final washing step sections were dehydrated in an ascending alcohol dilution 
series 70% - 80% - 96% ethanol (10 seconds each), 100% ethanol (twice 5 
minutes each) and Roti Histol for 5 minutes and mounted with Roti-Histokitt. 
For Giemsa staining slides were washed in distilled water following 
deparaffinization and incubated in Giemsa staining solution for 30 minutes, 
again washed in distilled water and incubated twice in aqueous acetic acid for 3 
seconds each. Sections were dehydrated in an ascending alcohol dilution series 
(96% ethanol twice for 3 seconds, 100% ethanol twice for 5 seconds and Roti 
Histol 5min) and mounted with a Roti-Histokitt. 
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2.5.2 Immunohistochemistry 
Biopsy-sections were also analyzed by immunhistochemistry. Immunhisto-
chemistry is a method used to detect antigens of interest in tissue samples. 
After binding of a primary antibody specific for the antigen a subsequent 
incubation with a biotinylated secondary antibody directed against the species 
of the primary antibody and adding avidin-peroxidase complexes leads to the 
accumulation of peroxidase at the antigen. Visualization of the antigen is 
achieved through a final incubation step with a peroxidase-sensitive color 
precursor compound. Oxidation of the compound causes precipitation of color 
where the antigen is present in the sample. 
An avidin-biotin-immunoperoxidase method was used for immunohistochemistry 
according to the manufacturer’s protocol. Monoclonal antibodies against the 
following antigens were used to identify, localize and characterize mononuclear 
cell infiltrates [48]. 
 CD3 for T-cells 
 CD68 for macrophages 
 HLA-DR-α to assess MHCII expression on antigen-presenting immune 
cells 
 Grem1 was used to detect Grem1 expression in cardiomyocytes or 
macrophages 
After deparaffinization slides were incubated in boiling citrate buffer pH6 in the 
microwave three times for 5 minutes each for antigen retrieval. After cooling 
down, slides were washed in PBS three times for 5 minutes each. 
To inhibit endogenous peroxidase, slides were incubated in the dark for 15 
minutes in 3% hydrogen peroxide and then washed in PBS. Sections were 
circled with a hydrophobic barrier pen and incubated with serum free blocking 
reagent for 15 minutes to block unspecific binding of antibodies. After decanting 
the blocking solution, either primary antibody or a corresponding isotype (see 
table below) or PBS were pipetted and incubated for 1h at room temperature or 
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overnight at 4°C. Slides were then washed three times in PBS, 0.05% Tween 
for 5 minutes each. Afterwards sections were incubated with a biotinylated 
secondary antibody directed against the species of the primary antibody for 30 
minutes at room temperature and then washed three times in PBS, 0.05% 
Tween for 5 minutes each. Streptavidin-HRP was added on top of sections, 
incubated for 30 minutes at room temperature and washed three times in PBS, 
0.05% Tween, 5 minutes each. Sections were incubated with DAB-
Chromogenic-Solution for different times depending on primary antibody used 
(see list below), dipped in PBS to stop staining, counterstained in hemalum for 3 
minutes, incubated in running tap water for 10 Minutes then dehydrated in an 
ascending alcohol series and mounted with Roti-Histokitt. 
 








mouse anti human CD3 Mouse IgG1 Rabbit anti mouse 10 minutes 
mouse anti human CD68 Mouse IgG1 Rabbit anti mouse 5 minutes 
mouse anti human HLA-
DR-a 
Mouse IgG1 
Rabbit anti mouse 5 minutes 
rabbit anti human Gremlin Rabbit IgG Goat anti rabbit 5 minutes 
 
2.6. Histopathological analysis 
Histological analysis of suspected myocarditis followed the Dallas criteria 
defined as:  
i) lymphocytic infiltrates in association with myocyte necrosis in acute 
myocarditis 
ii) inflammatory infiltrates without microscopic signs of myocyte injury in 
chronic myocarditis [49, 55-60] 
Stained myocardial tissue sections were evaluated by a semiquantitative score 
scheme ranging from 1 (very low, if any expression) to 4 (ubiquitous very strong 
expression) for CD 68 and MHC II expression . Grem1 staining was classified 
“negative” (no / low expression, score 1 or 2) or “positive” (moderate / high 
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expression, score 3 or 4). Scores for Grem1 were obtained in a blinded manner 
from 1 to 2 sections for each staining by two blinded co-investigators [61, 62]. 
The amount of cardiac fibrosis was defined as an index [48].  
The percentage area of fibrosis in the section was obtained by dividing the sum 
of the fibrotic areas of the section by that of the total tissue area as described 
previously [63]. According to this fibrosis index, patients were classified as 
having no or mild, moderate, or severe myocardial fibrosis [48]. 
 
2.7 Molecular detection of viral genomes by nested PCR 
PCR is a method used to amplify DNA. As a diagnostic tool PCR is used to 
amplify minimal amounts of DNA to detect viral or bacterial infections. 
Basic PCR consists of 3 steps: 
 
1. Denaturation of a double-stranded DNA-template, usually at a high 
temperature around 95°C. 
2. Annealing of primers specific for the 3'-end of both strands of the DNA-
sequence of interest, forming an incomplete DNA-double strand. 
3. Elongation of the incomplete complementary DNA-strand by adding single 
deoxynucleoside triphosphates (dNTPs) at the 3'-end of the primers 
catalyzed by a thermostable DNA-polymerase, usually Taq-polymerase.  
 
Steps 1 through 3 are repeated up to 35 times. Under optimal conditions each 
cycle would double the amount of DNA present at the start of the cycle resulting 
in an exponential amplification with 2n-fold amplification after n cycles [64]. 
Unspecific binding of the primers can cause unspecific amplification of DNA 
which can be interpreted as false positive results. To increase amplification 
specificity necessary for reliable diagnoses a nested PCR protocol was used. 
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Nested PCR consists of two PCR reactions with 2 sets of primers. After a first 
amplification of sample DNA with the first primer set the product of this reaction 
is used as template for a second PCR with a second set of primers. 
Consequently, in the product of the second PCR the contamination of DNA 
fragments which are products of the non-specific DNA amplification is reduced. 
Nested PCR was carried out at the Institut für Molekulare Pathologie in 
Tübingen, Germany. It was performed on deep-frozen or RNAlater-fixed 
endomyocardial biopsy samples according to manufacturer's protocol [56]. 
A biopsy was considered positive for viral infection, if viral genome was 
detected by nested PCR [65]. Samples were tested for influenza A and B, 
adenoviruses, parvovirus B19, enterovirus species (comprising coxsackie 
viruses and echo viruses), human herpes virus type 6, 7 and 8, herpes simplex 
virus, human cytomegalovirus, varicella-zoster virus, and Epstein-Barr virus.  
 
2.7.1  RNA preparation and Real-Time-quantitative PCR 
(qPCR) analysis 
In a qPCR specific sequences of a copy DNA (cDNA) are amplified using 
specific primers in the same way as in a basic PCR (see 2.7). The amplified 
sequences form DNA double strands (dsDNA) which bind SYBR-Green. SYBR-
Green can be excited by light of 494nm wavelength and emits light of 521nm 
wavelength. Binding of SYBR-Green by dsDNA causes a local concentration of 
SYBR-Green resulting in a stronger signal compared to the background of free 
unbound SYBR-Green. With increased cycle count the amplification of primer 
defined cDNA grows exponentially which in turn causes an increase in 
fluorescence of dsDNA bound SYBR-Green. The timepoint at which the SYBR-
Green fluorescence is stronger than the background signal is defined as the 
threshold cycle or Ct. By comparing Ct values for genes of interest compared to 
Ct values reference genes the relative gene expression strength can be 
calculated using the formula 2(- Ct). Gene expression of reference genes needs 
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to be constant and not be influenced by external stimuli. So called “house-
keeping” genes which are expressed constitutively in cells are chosen as 
reference genes. For this qPCR Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was chosen as reference gene. 
Quantitative real-time PCR (qPCR) was performed to measure the relative 
strength of expression of Gremlin1 in mouse embryonic cardiomyocytes HL-1 
compared to a reference gene. Total RNA was extracted from HL-1 cells using 
the RNEasy kit and reverse-transcribed into cDNA with the Im-Prom IIReverse 
Transcription System . 20 ng of cDNA were amplified with the iQ SYBR Green 
Supermix on an iCycler iQ using GAPDH as reference. Relative gene 
expression levels were quantified using the formula 2-(Ct(Grem1) - Ct(gapdh)). 
 
2.8 Sodiumdodecylsulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western Blotting 
2.8.1 SDS-PAGE 
Cell lysates were analyzed using SDS-PAGE. For this cell lysates are boiled 
under reducing conditions in order to denature their secondary and tertiary 
structures. At the same time proteins are given a negative charge by uniformly 
covering them with SDS, masking their own negative or positive electrical 
charges. 
Boiled lysates are then loaded onto a polyacrylamide gel near the cathode and 
an electric current is applied. Due to their uniform negative electric charge the 
proteins migrate in the electrical field through the gel towards the anode. 
Proteins move through the gel at different speeds because of the mesh formed 
by acrylamide monomers upon polymerization. Smaller proteins are held back 
less than larger proteins resulting in a separation of the proteins in the lysate 
according to their size over the length of the gel. Acrylamide concentration can 
be varied according to desired resolution of separation. A higher concentration 
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results in a better separation of smaller proteins while a lower concentration 
would be used to separate larger proteins [66, 67]. 
A variation of the SDS-PAGE is the discontinuous SDS-PAGE. Here proteins 
are first concentrated in a collecting gel with a lower concentration of acrylamide 
and then separated in a separating gel with a higher acrylamide concentration. 
 
2.8.1.1 SDS-PAGE protocol 
30µg of HL1-cardiomyocyte cell lysate were separated using discontinuous 
SDS-PAGE with 1x running buffer. Lysates were boiled for 10 minutes at 95°C 
under reducing conditions using 5x Laemmli-buffer supplemented with 5% b-
mercaptoethanol and then loaded onto a gel consisting of a collecting gel with a 
concentration of 4% acrylamide and a separating gel with a concentration of 
15%. 
2.8.2 Western Blot (WB) 
Western blotting is a technique used to identify proteins in a cell lysate following 
separation by SDS-PAGE. Separated proteins are transferred onto a protein 
binding membrane by applying through an electrical field (electroblotting). The 
gel and membrane are sandwiched between transfer-buffer soaked Whatman-
papers with the membrane closer to the anode and the gel closer to the 
cathode. Application of an electric current causes the negatively charged 
proteins to move out towards the anode onto the membrane. After blotting 
specific membrane bound proteins can be made visible by immune detection 
(chemiluminescent or fluorescent). Incubation with a protein specific primary 
antibody followed by incubation with a secondary antibody directed against the 
primary antibody and carrying a reporter molecule leads to the detection of 
protein of interest. 
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2.8.2.1 Western Blot protocol 
Proteins were blotted onto a 0.45µm polyvinylidene difluoride (PVDF)-
membrane using a semi-dry blotter. After activation of the PVDF membrane in 
methanol the gel and membrane were sandwiched between two 3mm thick 
pieces of Whatman-paper soaked in 1x transfer buffer and placed in the blotting 
device with the membrane closer to the anode. Proteins were blotted for 75 
minutes with a constant current of 110 mA and 15V. The membrane was then 
blocked in 5% skim milk in PBS for one hour at room temperature. Murine 
Gremlin1 was detected with a polyclonal rabbit anti-mouse-Gremlin1 antibody 
used in a dilution of 1:1000 in 5% skim milk+0.1% Tween in PBS. Actin was 
used as internal loading control and detected with a polyclonal rabbit anti-
mouse-actin, diluted 1:1000 in 5% skim milk+0.1% Tween in PBS. Incubation 
with primary antibodies was carried out at room temperature for one hour. 
Membranes were then washed three times for 5 minutes in PBS+0.1% Tween 
and then incubated for one hour at room temperature with a secondary donkey 
anti-rabbit antibody, diluted 1:15.000 in 5% skim milk+0.1% Tween in PBS, 
carrying a marker protein for near infrared fluorescence detection. Near-
infrared-fluorescence detection on an infrared imaging system was carried out 
after washing again three times with PBS+0.1% Tween. 
 
2.9 Statistical analysis 
Continuous variables are expressed as mean ± standard deviation and were 
compared using the Mann–Whitney U-test. Categorical data are presented as 
proportions and were analyzed by chi-square test. Cox proportional-hazards 
regression analysis was performed to assess the association of risk factors with 
endpoint occurrence. For this analysis, continuous variables were dichotomized 
using the patients` median as cut-off values (LVEF<40%, LVEDD>53mm, 
NYHA ≥ II, TnI>0.03 µg/l, and BNP >269 ng/l). After univariate analysis, 
statistically significant variables (p<0.05) were forced to enter the multivariate 
model, which was adjusted for age and gender. Survival curves of patients were 
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calculated by Kaplan-Meier analyses and compared using the Log-Rank test. 
The risk for endpoint occurrence is presented as hazard ratio (HR) with 95% 
confidence interval (CI). Time point for begin of survival analysis was the date of 
the endomyocardial biopsy. Correlation of expression of Grem1 and grade of 
fibrosis was tested by Spearman correlation.  Comparisons were considered 
statistically significant, if the two-sided p value was < 0.05. Statistical analyses 
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3. Results 
3.1 Patient population and risk factors 
We studied a consecutive cohort of 214 patients with structural myocardial 
disease not related to coronary artery disease. Immunohistological analysis 
showed that 160 of the patients (74.8%) were Grem1 positive and 54 (25.2%) 
were Grem1 negative. The demographic details and basic characteristics are 
presented in table 1 along with p-values comparing Grem1 positive and 
negative groups. There was no significant difference in the distribution of the 
clinical characteristics between the Grem1 positive and Grem1 negative groups, 
except for the mean LVEDD, LVEF and CRP. 
Patients showed a mean age of 52 (44-66) years, with a mean age of 52 years  
in the Grem1 positive and Grem1 negative group as well (p=0.856). 25.7% of all 
patients were female and they were equally distributed in the two groups, 26.3% 
in the Grem1 positive group and 24.1% in the Grem1 negative group (p=0.752). 
Mean BMI of the patients was 26 (23-29), with no significant difference in the 
Grem1 positive and Greml1 negative groups (p=0.764) and 82.2% of the 
patients entering the study were experiencing heart failure NYHA class ≥ II, with 
81.9% of the Grem1 positive and 83.3% of the  Grem1 negative patients 
experiencing heart failure NYHA ≥ II (p=0.808).  
The concomitant cardiac medication at study entry was the typical heart failure 
therapy with 78.5% of the patients taking -blockers, 69.2% ACE-inhibitors, 
17.3% ARB, 59.3% diuretics and 48.1% aldosterone antagonists. The cardiac 
medication was almost equally distributed in the Grem1 positive and negative 
group with p values of p=0.194 for -blockers, p=0.203 for ACE-inhibitors, 
p=0.890 for ARB, p=0.988 for diuretics and p=0.059 for aldosterone 
antagonists. 
Patients showed mean LVEDD 53(44-59) mm and mean LVEF 41(30-55) %. 
Between the group of Grem1 positive and Grem1 negative patients there was a 
significant difference in the distribution of mean LVEDD and LVEF with Grem1 
  40 
positive patients having a mean LVEDD of 54mm and LVEF of 40% in 
comparison to the Grem1 negative patients with a mean LVEDD of 49mm and 
LVEF of 50% with p=0.030 and p=0.001 respectively.  
Mean BNP values were 269 (73-548) ng/l, mean TnI 0.001 (0.001-0.11) µg/l, 
mean CK 97 (63-153) U/l and mean CRP 0.6 (0.1-1.6) mg/dl. There was no 
significant difference in the distribution of BNP (p=0.882), TnI (p=0.268) and CK 
(p=0.516) in the two groups.  CRP was found to be significantly increased in the 
Grem1 positive patients with a mean CRP of 0.7mg/dl in comparison to the 
Grem1 negative patients with a mean CRP of 0.4mg/dl (p=0.015). 
PCR analysis showed that 33.2% of myocardial biopsies were virus-positive; 
9.8% EBV, 16.8% PBV, 8.9% HHV 6, 0.5% Influenza A and B and 0.9% CVB3. 
The distribution of virus positive biopsies in the Grem1 positive and negative 
group was almost equal with no significant difference between the two groups 
with p=0.492 for EBV positive, p=0.381 for PVB19 positive, p=0.909 for HHV6 
positive, p=0.560 for influenza A/B positive and p=0.418 for CVB3 positive 
biopsies. 
Further immunohistological analysis showed that 107 (50.0%) of all patient 
biopsies were CD 68/CD3/MHC II positive. 52.5% of Grem1 positive and 42.6% 
of Grem1 negative patients were found to be CD 68/CD3/MHC II positive 
(p=0.208). 
 
Table 1. Baseline characteristics of the patient population, as published in [48] 
Parameters All Patients  
(n=214) 






Mean Age, y 52 (44-66) 52 (43-66) 52 (47-65) 0.856 
Females 55 (25.7%) 42 (26.3%) 13 (24.1%) 0.752 
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BMI (kg/m²) 26 (23-29) 26 (23-30) 26 (24-29) 0.764 
NYHA ≥II 176 (82.2%) 131 (81.9%) 45 (83.3%) 0.808 
Concomitant cardiac medication at study entry 
ß-Blockers 168 (78.5%) 129 (80.6%) 39 (72.2%) 0.194 
ACE-I 148 (69.2%) 119 (74.4%) 39 (72.2%) 0.203 
ARB 37 (17.3%) 22 (13.8%) 7 (13.0%) 0.890 
Diuretics 127 (59.3%) 95 (59.4%) 32 (59.3%) 0.988 
Aldosterone 
antagonists 
103 (48.1%) 83 (51.9%) 20 (37.0%) 0.059 
Parameters of the left ventricle 
LVEF (%) 41 (30-55) 40 (30-50) 50 (39-59) 0.001 
LVEDD (mm) 53 (44-59) 54 (45-59) 49 (43-56) 0.030 
Biomarkers     
BNP (ng/l) 269 (73-548) 260 (86-556) 285 (55-498) 0.882 
TnI (µg/l) 0.001 (0.001-
0.11) 
0.03 (0.001-0.11) 0.001 (0.001-
0.12) 
0.268 
CK (U/l) 97 (63-153) 96 (64-144) 101 (62-178) 0.516 
CRP (mg/dl) 0.6 (0.1-1.6) 0.7 (0.2-1.7) 0.4 (0.1-1.1) 0.015 
Virus-positive endomyocardial biopsies 
Total 71 (33.2%) 54 (33.8%) 17 (31.5%) 0.760 
EBV 21 (9.8%) 17 (10.6%) 4 (7.4%) 0.492 
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PVB19 36 (16.8%) 29 (18.1%) 7 (13.0%) 0.381 
HHV 6 19 (8.9%) 14 (8.8%) 5 (9.3%) 0.909 
Influenza A/B  1 (0.5%) 1 (0.6%) 0 (0%) 0.560 
CVB3 2 (0.9%) 1 (0.6%) 1 (1.9%) 0.418 
Positive detection of immunohistological markers 
Inflammatory 
markers** 
107 (50.0%) 84 (52.5%) 23 (42.6%) 0.208 
 
Values are presented as n (%) or median (interquartile range). ACE-I, angiotensin-converting 
enzyme inhibitor; ARB, angiotensine receptor blocker; BMI, body mass index; BNP, brain 
natriuretic peptide; CRP, C-reactive protein; CK, creatinkinase; CVB3, coxsackievirus B3; EBV , 
Ebstein-Barr virus; HHV 6 , Human herpesvirus- 6; LVEDD , left ventricular enddiastolic 
diameter; LVEF , left ventricular ejection fraction; NYHA , New York Heart Association; PVB19 , 
Parvovirus B19; TnI, troponin I. 
* comparison of Grem1 positive and negative patients; * *CD68 or CD3 or MHCII. 
Cardiomyopathies were classified according to standardized clinical [1] and 
histological criteria [14] as shown in table 2. 
Table 2. Classification of cardiomyopathies according to clinical and histological 
criteria. 
Primary cardiomyopathy, n (%)  65 (30.4) 
DCM  44 (20.6) 
HNCM/HOCM  17 (7.9) 
RCM 3 (1.4) 
ARVC/D  1 (0.5) 
Secondary cardiomyopathy, n (%) 149 (69.6) 
iDCM  112 (52.3) 
Acute myocarditis  6 (2.8) 
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Transplant rejection  7 (3.3) 
Loeffler endocarditis  3 (1.4) 
Microvascular ischemic cardiomyopathy  10 (4.7) 
Cardiac amyloidosis  11 (5.1) 
 
Values are n (%). ARVC/D – arrhythmogenic right ventricular cardiomyopathy/dysplasia, DCM - 
dilative cardiomyopathy, HNCM – hypertrophic non-obstructive cardiomyopathy, HOCM – 
hypertrophic obstructive cardiomyopathy, iDCM – inflammatory dilative cardiomyopathy/chronic 
myocarditis, RCM – restrictive cardiomyopathy. 
 
Primary cardiomyopathy was found in 65 (30.4%) patients. Patients with 
primary cardiomyopathy presented with either DCM (n=44, 20.6%), HNCM or 
HOCM (n=17, 7.9%), RCM (n=3, 1.4%), and ARVC/D (n=1, 0.5%). 149 (69.6%) 
patients presented with secondary cardiomyopathy. Among these, inflammatory 
dilative cardiomyopathy (iDCM) was found in 112 (52.3%) patients. Six (2.8%) 
patients presented with acute myocarditis. Transplant rejection (n=7, 3.3%) or 
Loeffler endocarditis (n=3, 1.4%) was found in a minority of patients. 10 (4.7%) 
patients were diagnosed with microvascular ischemic cardiomyopathy and 11 
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3.2 Myocardial expression of Gremlin-1 and correlation 
between Gremlin-1 expression and the degree of 
myocardial fibrosis 
Protein expression of Grem1 was primarily found in mouse embryonic 




Figure 4. Protein expression of Grem1 in mouse embryonic cardiomyocytes (HL-1 cells) 
detected by immunoblotting and qPCR. On the right panel Grem1 expression in HL-1 cells is 
shown on the mRNA level by reverse transcriptase PCR (upper right panel: images of PCR 
products on agarose gel) and by quantitative real time PCR (lower right panel: Values of Grem1 




In addition, we detected a positive myocardial expression of Grem1 in 160 
(74.8%) patients out of 214 consecutive patients with structural myocardial 
disease in the immunohistochemical staining of myocardial tissue. 
Representative myocardial tissue sections of myocardium with mild, moderate 
and severe fibrotic remodeling are illustrated in Figure 5, as published in [48]. 
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Figure 5: Immunohistochemistry detecting Grem1 expression in human myocardial tissue 
sections of patients with structural myocardial diseases. Myocardial tissue sections were stained 
with hematoxylin and eosin (HE), anti-Grem1, isotype and PBS controls. Top row: Myocardial 
biopsie with no/ mild fibrosis with not significantly enhanced Grem1 expression. Middle row: 
myocardial biopsie with moderate fibrosis and moderately enhanced Grem1 expression. Bottom 
row: myocardial biopsie with severe fibrosis and strongly enhanced Grem1 expression [48].   
 
 
Image of mild fibrosis (top row) shows the staining of a patient with slightly 
reduced LVEF without signs of fibrosis. Here, Grem1 expression is not 
significantly enhanced. The myocardial staining of Grem1 and moderate fibrosis 
(middle row) depicts a patient with DCM without immunohistological signs of 
inflammation. In moderate fibrosis Grem1 expression is moderately enhanced. 
In contrast, Grem1 staining is strongly enhanced in the cardiomyocytes of a 
patient with severe fibrosis of the myocardium and signs of inflammation after 
acute myocarditis (bottom row) [48]. 
 
Of note, the levels of myocardial Grem1 expression significantly correlated with 
the degree of myocardial fibrosis (Spearman correlation coefficient r=0.619, 
p<0.0001, Figure 6), as published in [48] . Figure 6 depicts the distribution of 
Grem1 positive and Grem1 negative biopsies in patients with no or mild, 
moderate and severe fibrosis. 41 (19.1%) patients revealed no/mild myocardial 
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fibrosis. Among these, 34 (82.9%) patients were Grem1 negative and 7 (17.1%) 
were Grem1 positive. 105 (49.1%) patients showed moderate fibrosis. In this 
group, 15 (14.3%) were Grem1 negative and 90 (85.7%) were Grem1 positive. 
In 68 (31.8%) patients with severe fibrosis, 4 (5.9%) were Grem1 negative but 
64 (94.1%) were Grem1 positive. In patients with enhanced myocardial fibrosis 
protein expression of Grem1 was significantly increased compared to patients 
with no or mild fibrosis [48]. 
 
Figure 6: Distribution of Grem1 positive and Grem1 negative biopsies in patients with structural 
myocardial diseases according to the degree of myocardial fibrosis. Grem1 expression was 
significantly enhanced in patients with moderate and severe fibrosis in comparison to the 
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3.3 Association of endomyocardial expression of 
Gremlin-1 with left ventricular dysfunction 
We also analyzed clinical parameters in our patient cohort. Patients with 
enhanced Grem1 expression revealed a significantly reduced LVEF compared 
to patients with negative Grem1 staining (Grem1 positive vs Grem1 negative: 
LVEF 39.4% ± 13.8 vs 48.0% ± 14.5, p = 0.001, Figure 7A), as published in 
[48]. Furthermore, myocardial Grem1 expression was significantly associated 
with a higher LVEDD. Patients with positive Grem1 staining were found to have 
a significantly enlarged ventricle at study entry. (Grem1 positive vs. Grem1 
negative: LVEDD 53.1mm ± 10.2 versus 49.8mm ± 9.0, p = 0.03, Figure 7B), as 
published in [48] . 
 
 
Figure 7: Association of myocardial expression of Grem1 with left ventricular risk markers. (A) 
LVEF in Grem1 positive patients was significantly reduced compared to Grem1 negative 
patients (39.4% ± 13.8 vs. 48.0% ± 14.5, p = 0.001). (B) LVEDD was significantly increased in 
patients with positive Grem1 immunohistochemistry in comparison to patients with Grem1 
negative immunohistochemistry (53.1mm ± 10.2 vs. 49.8mm ± 9.0 in Grem1 negative patients, 
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3.4 Association of Gremlin-1 expression with poor clinical 
outcome/ Gremlin-1 as independent predictor of 
adverse cardiac events 
During follow-up  33 (15.4%) patients reached the combined end point (table 3). 
Out of these, 31 (93.9%) patients showed Grem1 positive myocardial staining 
and only 2 (6.1%) patients were Grem1 negative (p=0.006). 22 (10.3%) patients 
died. Out of these, 21 (95.4%) patients were Grem1 positive and 1(1.9%) was 
Grem1 negative (p=0.026). 11 (5.1%) patients were readmitted to the hospital 
due to heart failure, 10 (90.9%) of them were Grem1 positive (p=0.096), as 
published in [48]. 
Table 3. Clinical outcome during follow-up. 
  All Patients Grem1 positive Grem1 negative P** 
  (n=214) (n=160, 74.8%) (n=54, 25.2%)   
Combined endpoint* 33 (15.4%) 31 (19.4%) 2 (3.7%) 0.006 
All-cause death 22 (10.3%) 21 (13.1%) 1 (1.9%) 0.026 
HF-related 
rehospitalization 
11 (5.1%) 10 (6.3%) 1 (1.9%) 0.096 
 
 * combination of all-cause death and heart failure-related rehospitalization. 
 ** comparison of Greml1 positive and negative patients,  tested by Cox regression analysis. 
 
In Kaplan-Meier (Figure 8) are illustrated the estimates of the occurrence of the 
composite endpoint in relation to myocardial Grem1 expression. Grem1 
expression was significantly related to the clinical outcome (LogRank 10.7, 
p=0.001). Cumulative 1 year event rate was 13.3% in Grem1 positive vs 0% in 
Grem1 negative patients, 2 years event rate was 22.5% vs 0%, respectively, 
and 3 years event rate was 35.6% vs 7.7% (p <0.05 for all), as published in [48] 
. 
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Figure 8: Kaplan-Meier-Curves of occurrence of the composite endpoint (all-cause death and 
heart failure-related rehospitalization) stratified by Grem1 expression in the myocardium. 




In univariate analysis, expression of Grem1, expression of myocardial 
inflammatory markers (CD68, MHCII, and CD3), viral genome, reduced 
LVEF<40%, LVEDD >53mm, NYHA functional class ≥ II, TnI >0.03 μg/l and 
BNP >269 ng/l were tested for prediction of the study endpoint (table 4). Among 
these variables Grem1 expression and NYHA functional class ≥ II were 
significant predictors of the study endpoint (Hazard ratio (HR); 95% confidence 
interval (CI): (Grem1: HR 7.9; 95% CI 1.9–33.6; p=0.005; NYHA≥II: HR 2.2; 
95% CI 1.1–4.4; p=0.027) [48]. 
Multivariate analysis revealed that Grem1 expression remained an independent 
predictor of clinical outcome along with NYHA class ≥ II (Grem1: HR 7.5; 95% 
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CI 1.8–32.2; p=0.006; NYHA≥II: HR 2.0; 95% CI 1.0–4.1; p=0.048, (table 4), as 
published in [48]. 
Furthermore, the degree of myocardial fibrosis was tested as factor for 
prediction of the study end point. Of note, the degree of fibrosis was in contrast 
to Grem1 expression not significantly associated with outcome in univariate 
analysis (HR 1.8; 95% CI 0.8–4.0; p=0.204) [48].   
 
Table 4. Hazard ratios for prediction of combined endpoint [48]. 
  Univariate Analysis Multivariate Analysis 
Variable HR (95% CI) P HR (95% CI) P 
Grem1 positive 7.9 (1.9 - 33.6) 0.005 7.5 (1.8 - 32.2) 0.006 
Inflammatory markers 0.6 (0.3-1.3) 0.239     
Virus positive 0.8 (0.4-1.7) 0.607   
LVEF < 40% 0.9 (0.5 - 1.8) 0.785   
LVEDD > 53mm 1.1 (0.5-2.2) 0.803     
NYHA ≥ II 2.2 (1.1 - 4.4) 0.027 2.0 (1.0 - 4.1) 0.048 
TnI > 0.03µg/l 1.5 (0.8 - 3.14) 0.211   
BNP > 269ng/l 2.4 (0.7 - 8.4 ) 0.155   
 
combined endpoint = combination of all-cause death  and heart failure-related rehospitalization. 
CI – confidence interval, HR- hazard ratio 
 
The sensitivity and specificity of Grem1 expression for prediction of the 
combined endpoint was calculated with 93.9% and 28.7% respectively. The 
positive predictive value of Grem1 expression was 19.4%, the negative 
predictive value was 96.3% [48]. 
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4. Discussion 
Therapy and diagnosis of CM are a challenge in modern cardiology. Structural 
myocardial diseases show a poor prognosis. 80% of cases of SCD in young 
athletes is caused by either HCM or ARVC [68]. In children with an age below 
18 years, the overall incidence of CM is 1.13 cases per 100.000 [4]. According 
to the report of the AHA (2011 Update) 10 per 1000 population over 65 years of 
age suffer from a structural myocardial disease. At the same time heart failure is 
mentioned on one in 9 death certificates in USA in 2011 [4].  
One of the main causes leading to congestive or acute heart failure in CM is the 
process of cardiac remodeling of the heart muscle. Transformation of the 
structure of one or both ventricles leads to ventricle dysfunction and finally heart 
failure, life threatening arrhythmias and SCD. The quality of life of patients 
suffering from structural myocardial diseases gradually deteriorates leading to 
progressive limitation of everyday life. These patients are treated with long term 
medication, ICD implantation and in end stage disease with heart 
transplantation.  
As a BMP antagonist Grem1 inhibits BMP induced cell regeneration and 
apoptosis of myofibroblasts and causes an accumulation of ECM [37]. It also 
causes an upregulation of the pro- fibrotic TGF- signaling pathway leading to 
the conclusion that Grem1 overexpression could be a key player in chronic 
fibrotic remodeling ultimately causing organ failure [47]. 
Grem1 plays a crucial part in chronic fibrotic diseases of kidney, lung and liver 
especially in progressive fibrotic courses of the disease regulating various-
signaling pathways of regeneration involving BMPs and TGF-ß. In 2006 Koli et 
al. established that Grem1 was overexpressed in lung interstitium of patients 
with IPF [47]. One year later Mezzano et al. demonstrated that Grem1 
overexpression was correlated with tubulointerstitial fibrosis. The observed 
overexpression of Grem1 in tubular and infiltrating interstitial cells indicated that 
it may play a role in the fibrous process in crescentic nephritis [43]. The results 
of Boers et al. showed that Grem1 was not present in stellate cells of normal 
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liver but was strongly induced in activated human stellate cells of fibrotic liver. 
The enhanced expression of Grem1 in fibrotic liver suggests it as a possible 
specific marker of liver fibrosis [44]. However, Grem1 has not been described in 
structural myocardial diseases involving fibrotic remodeling so far.  
Since Grem1 is a BMP antagonist that plays a role in chronic fibrotic process in 
lungs, kidneys and liver and since myocardial fibrosis is a key step in the 
pathophysiology of myocardial remodeling, we hypothesized that the expression 
of Grem1 may play a role in CM and might have a predictive value in the 
diagnostic workup of patients with structural myocardial disease. 
The major findings of the present study are: 
i) Grem1 is highly expressed in the myocardium of patients with structural 
myocardial disease and correlates with fibrosis and impaired left ventricular 
function.  
ii) Grem1 expression in tissue derived from endomyocardial biopsies is an 
independent predictor of poor clinical outcome in patients with structural 
myocardial disease.  
These findings are the first to show that Grem1 might play a pathophysiological 
role in ventricular remodeling and may be a useful biomarker to evaluate 
disease progression. 
In the present study we were able to show for the first time that Grem1 is 
expressed in mouse embryonic cardiomyocytes as well as in a high percentage 
(74.8%) of human endomyocardial biopsies of unselected patients with 
structural myocardial disease. 
The level of Grem1 expression significantly correlated with the degree of 
myocardial fibrosis. Our results suggest that in patients with enhanced 
myocardial fibrosis protein expression of Grem1 is significantly increased 
compared to patients with no or mild fibrosis. Therefore it may be tempting to 
speculate that the expression of Grem1 is only reflecting the presence of 
fibrosis. However, the expression of Grem1 in the myocardium was an 
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independent predictor of the combined endpoint whereas the degree of fibrosis 
was not significantly related to the outcome of the patients [48]. 
Patients who were Grem1 positive had a more severe left ventricular 
dysfunction. This was clinically expressed by a lower LVEF and a higher 
LVEDD. Therefore, we assume that Grem1 may play a role in the 
pathophysiological procedure of ventricular remodeling of structural myocardial 
disease. 
Apart from Grem1 expression, univariate analysis was also performed in seven 
other factors (inflammatory markers, viral genome, LVEF <40%, LVEDD 
>53mm, NYHA ≥ II, TnI >0.03 μg/l, and BNP >269 ng/l) connected with the 
severity of CM and fibrosis in order to ascertain their respective prognostic 
value. 
In contrast to previous findings [57], immunohistological detection of 
inflammation (CD3, CD68, MHC class II molecules) did not allow the prediction 
of adverse events in our cohort (p=0.239), which might reflect the differing 
patient selection criteria in our study that consecutively enrolled various entities 
of structural myocardial diseases [48]. 
The diagnostic and prognostic relevance of the detection of viral genome 
remains a matter of debate [54, 57]. In our patient cohort, approximately one 
third of endomyocardial biopsies were virus positive. However, virus genome 
detection was not predictive for the occurrence of clinical events during the time 
of follow-up (p=0.607) [48]. 
Established clinical risk markers were also evaluated in our patient cohort. 
Increased LVEDD is a parameter of systolic LV dysfunction and is shown to be 
increased in DCM. BNP is a proven, highly sensitive marker for heart failure [69] 
as it is secreted when myocytes are excessively stretched. LVEDD >53mm 
(p=0.803) and BNP>269 ng/l (p=0.155) were not found to have a significant 
correlation with the study end point. 
One explanation, why BNP is not a predictor of clinical outcome in our cohort 
may be due to the design of our study, as our cohort included patients with 
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structural myocardial disease (including e.g. HOCM, HNCM, secondary CM due 
to amyloidosis) and not necessarily patients with heart failure where BNP is a 
well-known predictor of outcome. A significant proportion of patients in our study 
had normal LVEF. Hence, values of BNP widely differed between our patients 
and that might explain why BNP is not an independent predictor of outcome in 
our cohort. The lack of correlation between BNP and outcome could even 
strengthen the importance of Grem1 as a prognostic biomarker. As Grem1 
expression showed a correlation with outcome but BNP didn’t it can be 
speculated that Grem1 could be used to detect cardiomyopathies at an early 
stage, possibly early enough to control its severity by treatment. 
Advanced NYHA functional class is a clinical sign of heart failure, representing 
patients with a slight or marked limitation of physical activity. NYHA ≥ II was an 
independent predictor of study end point (p=0.027). An elevated level of TnI is a 
marker of myocardial necrosis and heart failure.  TnI > 0.03µg/l was not found 
to be significantly correlated with the study endpoint (p=0.211) [70-72]. 
Although decreased systolic LVEF is a significant standard parameter of 
systolic dysfunction, LVEF< 40% appeared to be not of predictive value in our 
cohort (p=0.785). This may be due to our study design that included 
consecutive patients with structural myocardial disease who did not necessarily 
have decreased LVEF (e.g. patients with HNCM, HOCM, RCM, ARVC/D or 
storage disease). 
Furthermore, we assessed the predictive value of cardiac fibrosis for the study 
end point. Of note, the degree of fibrosis was in contrast to Grem1 expression 
not significantly associated with outcome in univariate analysis (HR 1.8; 95% CI 
0.8–4.0; p=0.204). In conclusion, although expression of fibrosis and expression 
of Grem1 was highly correlated, fibrosis was no predictor of outcome in our 
patient cohort in contrast to Grem1. Therefore, the evidence of a Grem1 
positive biopsy may comprise more prognostic information beyond that of the 
degree of fibrosis within the myocardium.  
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While the sensitivity of Grem1 (93.9%) for the prediction of adverse clinical 
events was high, the specificity (28.7%) and positive predictive value (19.4%) 
were quite low [48]. This might be due to the fact that 74.8% of patients were 
Grem1 positive. Nevertheless, the negative predictive value was high (96.3%) 
for the prediction of combined endpoint [48]. The fact that patients with no or 
low Grem1 expression showed an excellent prognosis in the long-term follow-up 
indicates that Grem1 is involved in pathophysiological mechanisms of 
myocardial remodeling in patients with structural myocardial disease.  
Therefore we draw the conclusion that especially the absence of Grem1 has 
clinical implications as these patients have a far better outcome compared to 
Grem1 positive patients. These results could lead to an improvement of risk 
stratification and better treatment options at an early stage of the disease, as 
the absence of Grem1 expression may help to identify patients at low risk for 
adverse clinical events in contrast to patients with Grem1 who benefit from an 
intensified monitoring. These new findings are of importance in cardiovascular 
research, as we demonstrate that Grem1 could be used as a novel diagnostic 
and prognostic marker of myocardial disease.  
Furthermore, Grem1 could be examined as a possible serum biomarker for the 
non-invasive assessment of myocardial fibrosis. Common serum biomarkers 
like PINP, PIIINP, PICP, ICTP are currently used in clinical routine and it is 
speculated that they may reflect collagen synthesis or degradation in the 
myocardium of heart failure patients. The unreliability of these markers makes 
the non-invasive assessment of fibrosis problematic at the moment [72]. 
Mechanistic studies should be performed to further evaluate not only the impact 
of Grem1 as serum biomarker in the non-invasive assessment of myocardial 
fibrosis but also the prediction of adverse outcome in patients with structural 
myocardial disease.  
Our study may also open the way for the development of new therapeutic 
strategies to control and prevent inflammatory heart diseases involving 
remodeling mechanisms such as heart failure, one major challenge for the 
western medicine in the future. 
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5. Summary 
Gremlin-1 (Grem1), an antagonist of bone morphogenetic proteins, is involved 
in fibrotic tissue formation in kidney, lung and liver. The impact of myocardial 
Grem1 expression is unknown. Therefore, we investigated the diagnostic and 
prognostic value of Grem1 in structural myocardial diseases. 
214 patients with structural myocardial diseases consecutively underwent 
endomyocardial biopsy. Standard histopathology, Grem1 expression and 
degree of myocardial fibrosis (no/mild, moderate, severe) were assessed with 
immunohistology. Prognostic risk factors included markers for immuno-
histological detection of inflammation (CD3, CD68, MHC class II molecules), 
viral genome, LVEF, LVEDD, NYHA functional class, TnI and BNP. The study 
endpoint was defined as a combination of death of all causes or heart failure-
related re-hospitalization within a follow-up period of 3 years. 
Grem1 expression correlated significantly with the degree of myocardial fibrosis 
(Spearman correlation coefficient r = 0.619, p<0.0001). There was no 
significantly enhanced Grem1 expression in patients with only mild fibrosis 
whereas biopsies of patients with moderate to severe fibrosis showed a 
moderately to strongly enhanced Grem1 expression. Grem1 positive patients 
showed an impaired LVEF (39.4±13.8% vs. 48.0±14.5%, p=0.001) and a larger 
LVEDD (53.1±10.2mm vs. 49.8± 9.0mm, p=0.03). During follow-up 33 (15.4%) 
patients reached the combined endpoint. In multivariate analysis, Grem1 
expression and NYHA≥II were independent predictors of the study endpoint 
(Grem1: Hazard ratio (HR) 7.5; 95% confidence interval (CI) 1.8–32.2, p=0.006; 
NYHA≥II: HR 2.0; 95% CI 1.0–4.1, p=0.048).  In contrast to Grem1 expression, 
the degree of myocardial fibrosis was not significantly associated with outcome 
in univariate analysis (HR 1.8, 95% CI 0.8-4.0; p=0.204).  
Therefore, Grem1 is an independent predictor of adverse outcome in patients 
with structural myocardial disease and may serve as new immunohistochemical 
biomarker. 
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6. Zusammenfassung 
Gremlin-1 (Grem1) ist ein BMP-Antagonist, der bei fibrotischen 
Umbauprozessen der Niere, Lunge und Leber eine Rolle spielt. Der Einfluss der 
Grem1-Expression auf das Myokard ist derzeit nicht bekannt. Deswegen wurde 
in der vorliegenden Studie die diagnostische und prognostische Rolle von 
Grem1 in der strukturellen Herzerkrankung untersucht.  
Bei 214 Patienten mit struktureller Herzerkrankung wurden Myokardbiopsien 
entnommen. Histopathologische Standarduntersuchung, die Grem1-Expression 
und der Grad der Fibrose im Herzmuskel wurden mittels Immunhistochemie 
analysiert. Zu den untersuchten prognostischen Risikofaktoren zählten Marker 
zur immunhistologischen Detektion von Inflammation  (CD3, CD68, MHC-II), 
Detektion viraler Genome, die linksventrikuläre Ejektionsfraktion (LVEF), der 
linksventrikuläre enddiastolische Durchmesser (LVEDD), die NYHA 
Klassifikation, Troponin I (TnI) und Brain Natriuretic Peptide (BNP). Der  
Studien-Endpunkt wurde als Kombination von Tod oder Rehospitalisation 
aufgrund von Herzinsuffizienz innerhalb eines Nachverfolgungszeitraums von 3 
Jahren definiert. 
Es zeigte sich eine signifikante Korrelation zwischen dem Grad der Grem1 
Expression und dem Grad der Herzmuskelfibrose (Korrelationskoeffizient nach 
Spearman r=0.619, p<0.0001). Bei Patienten mit leichter Fibrose gab es keine 
signifikant erhöhte Expression von Grem1, dagegen fand sich in Biopsien von 
Patienten mit mittlerer bis schwerer Fibrose eine mittelmäßig bis stark erhöhte 
Grem1 Expression. Es konnte gezeigt werden, dass eine erhöhte Grem1 
Expression mit einer eingeschränkten LVEF (39.4±13.8% vs. 48.0±14.5%, 
p=0.001) und einem vergrößerten LVEDD (53.1±10.2mm vs. 49.8± 9.0mm, 
p=0.03) signifikant korrelierte. Während der Nachverfolgungszeit  erreichten 33 
(15.4%) Patienten den kombinierten Endpunkt.  In multivariablen Analyse 
erwiesen sich die  Grem1 Expression und eine NYHA-Klasse ≥II als 
unabhängige prognostischen Faktoren für das Erreichen des Endpunktes 
(Grem1: Hazard ratio (HR) 7.5; 95% confidence interval (CI) 1.8–32.2, p=0.006; 
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NYHA≥II: HR 2.0; 95% CI 1.0–4.1, p=0.048). Im Gegensatz zur Grem1-
Expression war der Grad der myokardialen Fibrose in einer univariaten Analyse 
nicht signifikant mit dem Ausgang assoziiert. (HR 1.8, 95% CI 0.8-4.0; 
p=0.204).  
Daher kann Grem1 als neuer unabhängiger prognostischer Biomarker für das 
Auftreten kardiovaskulärer Ereignisse bei Patienten mit struktureller 
Herzmuskelerkrankung dienen und in die immunhistologischen Routine-
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8.  Index of abbreviations 
 
ACC   American College of Cardiology 
ACE   Angiotensin-converting-enzyme 
AHA   American Heart Association 
ARVC                        Arrhythmic right ventricular cardiomyopathy 
ΑRB                         Angiotensin  receptor blocker 
BMI                         Body mass index 
BMP                         Bone morphogenetic protein  
BNP                         Brain natriuretic peptide 
CD                           Cluster of Differentiation  
cDNA                      Complementary DNA 
CI                            Confidence interval  
CK                          Creatine kinase 
        CKD                       Chronic kidney disease 
CM                           Cardiomyopathy 
CMR                        Cardiovascular magnetic resonance 
COPD                      Chronic obstructive pulmonary disease 
coSmad                   Common Smad 
CRP                        C-reactive protein 
CypA                      Cyclophilin A  
CypB                       Cyclophilin B 
DCM                        Dilated cardiomyopathy 
DNA                         Deoxyribonucleic acid 
dNTPs                     Deoxynucleoside Triphosphates 
dsDNA                    Double strands DNA 
ECM                        Extracellular matrix  
EMMPRIN  Extracellular Matrix Metalloproteinase inducer 
EMT                       Epithelial to mesenchymal transition 
ESC                 European Society of Cardiology 
GAPDH   Glyceraldehyde 3-phosphate dehydrogenase 
Grem1                    Gremlin-1 
HCM                       Hypertrophic cardiomyopathy 
HCV                        Hepatitis C Virus 
HE                          Haematoxylin and Eosin 
HF                          Heart failure 
HNCM    Hypertrophic non-obstructive cardiomyopathy 
HOCM   Hypertrophic obstructive cardiomyopathy 
HR                           Hazard ratio  
HSC                        Hepatic stellate cells  
HTX                        Heart transplantation 
ICD                         Implantable cardioverter defibrillator  
ICTP                        C-terminal telopeptide of collagen I 
iDCM                       Inflammatory dilative cardiomyopathy 
IGF                          Insulin-like growth factor  
IL                             Interleukin 
IPF                         Idiopathic pulmonary fibrosis 
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LGE   Late gadolinium enhancement 
LV   Left ventricle 
LVEDD                    Left ventricular enddiastolic diameter 
LVEF                       Left ventricular ejection fraction 
MHC-II   Major Histocompatibility Complex 
MMP                       Matrix metalloproteinase 
NCCM                     Non compaction cardiomyopathy 
NSVT                      Non-sustained ventricular tachycardia 
NYHA                      New York Heart Association 
NPV                        Negative predictive value  
PBS   Phosphate buffered saline 
PCR   polymerase chain reaction 
PDGF                     Platelet derived growth factor 
PICP                        C-terminal propeptide of collagen type I 
PINP                        N-terminal peptide of collagen type I 
PIIINP                      N-terminal peptide of collagen type III  
PPV                        Positive predictive value 
PVDF                      Polyvinylidene difluoride  
qRT-PCR                Real-Time-quantitative PCR 
RCM                        Restrictive cardiomyopathy 
ROS                        Reactive oxygen species 
R-Smad                  Receptor- associated Smad 
RV                           Right ventricle 
RVOT                      Right ventricular outflow tract 
SDS-PAGE  Sodiumdodecylsulfate polyacrylamide  
 gel electrophoresis 
SCD                        Sudden cardiac death 
Smad   Small tail and mothers against decapentaplegic 
TGF 1                     Transforming growth factor beta1 
TIMP                       Tissue inhibitor of metalloproteinases 
TNF                         Tumor necrosis factor 
TnI                           Troponin I 
VT                           Ventricular tachycardia 
VF                          Ventricular fibrillation 
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